Amarin | AMRN - نسبة السعر إلى الأرباح





Pe تغيير تاريخ
AbbVie 23.03 1 2026-03
Alnylam Pharmaceuticals 80.04 90.66 2026-03
Amarin 91.05 88.3 2023-06
AstraZeneca 29.59 2.3 2026-03
BioCryst Pharmaceuticals 6.06 1.07K 2025-12
GlaxoSmithKline 14.87 3.72 2026-03
Halozyme Therapeutics 11.35 11.8 2026-03
Ionis Pharmaceuticals 396.15 79.28 2022-09
Neurocrine Biosciences 28.09 807.38 2026-03
Novartis 20.17 2.32 2026-03